FMUs-oriented Subcompartment Data Sharing Technology

This article takes a forestry company in Heyuan City of Guangdong Province for example,to research the FMUs(Forest Management Units)-oriented subcompartment data sharing technology,and realize the software platform based on Visual Basic development environment.The software platform can perform the normalization processing,cadastral number coding,data extraction,data updating and other pragmatic operations on subcompartment data,so as to achieve the subcompartment data sharing between forest management unit and Guangdong forest resources center.

Long-range Dependence Characteristics of Forest Biological Disasters in China against the Background of Climate Change

Forest biological disasters(FBD) seriously impact energy flow and material cycling in forest ecosystems,while the underlying causes of FBD are complex. These disasters involve large areas and cause tremendous losses. As a result,the occurrence of FBDs in China( CFBD) threatens the country's ability to realize its strategic target of increasing both forested area(40 million ha) and forest volume(1.3 billion m^3) from 2005 to 2020. Collectively,China has officially named this effort to increase forest area and volume the "Two Increases" as national goals related to forestry. Based on Hurst index analysis from fractal theory,we analyzed the time series of the occurrence area and related data of FBDs from 1950 to 2007 to quantitatively determine the patterns of the macro occurrence of FBDs in China. Results indicates that,the time series of( CFBD) areas is fractal( self-affinity fractal dimension D = 1. 3548),the fluctuation of( CFBD) areas is positively correlated( auto-correlation coefficient C = 0. 2170),and the occurrence of the time series of( CFBD) is long-range dependent( Hurst index H =0. 6416),showing considerably strong trend of increases in FBDC area. Three different methods were further carried out on the original time series,and its two surrogate series generated by function surrogate in library t series,and function Surrogate Data in library in Wavelet software R,so as to analyze the reliability of Hurst indexes. The results showed that the Hurst indices calculated using different estimation methods were greater than 0. 5,ranging from 0. 64 to 0. 97,which indicated that the change of occurrence area data of FBDs was positively autocorrelated.The long-range dependence in forest biological disasters in China is obvious,and the spatial extent of FBDs tended to increase during this study period indicating this trend should be expected to persistent and worsen in the future.

First-line camrelizumab(a PD-1 inhibitor)plus apatinib(an VEGFR-2 inhibitor)and chemotherapy for advanced gastric cancer(SPACE):a phase 1 study

Patients with advanced gastric cancer typically face a grim prognosis.This phase 1a(dose escalation)and phase 1b(dose expansion)study investigated safety and efficacy of first-line camrelizumab plus apatinib and chemotherapyfor advanced gastric or gastroesophageal junction adenocarcinoma.The primary endpoints included maximum tolerated dose(MTD)in phase 1a and objective response rate(ORR)across phase 1a and 1b.Phase 1a tested three dose regimens of camrelizumab,apatinib,oxaliplatin,and S-1.Dose regimen 1:camrelizumab 200 mg on day 1,apatinib 250 mg every other day,oxaliplatin 100 mg/m^(2) on day 1,and S-140 mg twice a day on days 1-14.Dose regimen 2:same as dose regimen 1,but oxaliplatin 130mg/m.Dose regimen3:same as dose regimen 2,but apatinib 250 mg daily.Thirty-four patients were included(9 in phase 1a,25 in phase 1b).No dose-limiting toxicities occurred so no MTD was identified.Dose 3 was set for the recommended phase 2 doses and administered in phase 1b.The confrmed ORR was 76.5%(95%CI 58.8-89.3).The median progression-free survival was 8.4 months(95%CI 5.9-not evaluable[NE]),and the median overall survival(OS)was not mature(11.6-NE).Ten patients underwent surgery after treatment and the multidisciplinary team evaluation.Among 24 patients without surgery,the median OS was 19.6 months(7.8-NE).Eighteen patients(52.9%)developed grade≥3 treatment-emergent adverse events.Camrelizumab plus apatinib and chemotherapy showed favorable clinical outcomes and manageable safety for untreated advanced gastric cancer(ChiCTR2000034109).

PEGylated carbon dot/MnO_2 nanohybrid: a new pH/H_2O_2-driven, turn-on cancer nanotheranostics

The effect of tumor-targeted photodynamic therapy（PDT） was improved by designing nanotheranostics to promote oxygenation in a tumor microenvironment（TME）wherein hypoxia, acidosis, and the elevated levels of H2O2 are three main characteristics. In this study, a carbon dot（CD）PDT agent recently developed by our group was firstly applied as reducing agent to react with potassium permanganate for fabricating CDs/manganese dioxide（CDs/MnO2） composites,which were in turn modified with polyethylene glycol（PEG） to form water-soluble CDs/MnO2-PEG nanohybrids. In a normal physiological environment, the as-prepared nanohybrids exhibited quenched fluorescence, weak singlet oxygen generation, and low magnetic resonance imaging（MRI） signal.However, given the high sensitivity of MnO2 to the TME, the CDs/MnO2-PEG nanohybrids changed from an ＂off＂ to an＂on＂ state with synchronously enhanced fluorescence, singlet oxygen generation, and MRI signal in the TME. In vitro and in vivo analyses have revealed that CDs/MnO2-PEG nanohybrids could be applied as TME-driven, turn-on nanotheranostics for the MR/fluorescence bimodal imaging-guided PDT of cancer.Moreover, complete clearance of CDs/MnO2-PEG nanohybrids from the body of mice was observed, indicating their low long-term toxicity and good biocompatibility. This work offers a new nanotheranostic candidate for modulating the unfavorable TME, particularly for the targeted PDT of cancer through precise positioning and oxygen generation.

Characterization of DNA damage response deficiency in pancreatic cancer patients from China

To the editor,Pancreatic ductal adenocarcinoma(PDAC)has the worst prognosis among all common malignant solid tumors,with a 5-year overall survival(OS)rate of less than 10%[1].Few effective targets for anticancer ther-apy have been confirmed in pancreatic cancer.Recently,it was substantiated that pancreatic cancer patients carry-ing deleterious mutations of the DNA damage response(DDR)genes are more likely to benefit from platinum-based chemotherapy[2]and poly(adenosine diphosphate-ribose)polymerase(PARP)inhibitor[3].